HENRY SCHEIN INC (HSIC): 10-K filed February 25, 2025

AI analysis of the 10-K that HENRY SCHEIN INC filed with the U.S. SEC on February 25, 2025, grounded in the primary-source EDGAR filing.

• Opioid Litigation Quantified: Company disclosed maximum contingent liability capped at 0.4% of sales, marking first-time transparency on opioid exposure; confirms material but bounded legal risk in healthcare distribution segment

• Interest Rate Vulnerability: Heavy reliance on variable-rate SOFR-indexed debt across multiple facilities with no disclosed hedging strategy exposes earnings to volatility in current elevated rate environment

• Working Capital Refinancing Risk: Material dependency on accounts receivable securitization (ABCP facility) for liquidity creates potential vulnerability if credit markets tighten or spreads widen unexpectedly

• Neutral Management Posture: Measured disclosure tone suggests management confidence in risk containment, though limited data suggests investors should seek additional color on debt maturity ladder and hedging intentions

Filing analysis — key questions

Answers are generated from this SEC filing and StockHuntr's analysis. Not investment advice.

What does HENRY SCHEIN INC (HSIC)'s 10-K filed February 25, 2025 say?

Company Overview: Henry Schein Inc is a wholesale distributor of medical, dental, and hospital equipment and supplies (SIC 5047), headquartered in Melville, NY, trading on NASDAQ under ticker HSIC with fiscal year ending December 28, 2024 Business Segments: The company operates multiple business segments including a Global Technology segment, with operations spanning medical/dental distribution…

Is HSIC's 10-K bullish or bearish?

Our analysis rates this filing CAUTIOUS. Henry Schein Inc presents an ELEVATED concern profile driven by multiple interconnected financial and legal risks. The opioid litigation exposure, while quantified, remains a material contingent liability in an industry-wide legal environment with…

How concerning is HSIC's latest 10-K?

Concern level: HIGH (6.2/10). Key factors: One high-severity risk identified: Opioid litigation exposure (severity 7/10) with ongoing MDL involvement and uncertain resolution timeline, despite quantified 0.4% maximum sales cap; Three moderate-to-high severity risks: variable-rate debt dependency (SOFR-indexed across multiple facilities), accounts receivable securitization reliance creating…

What are the main risks flagged in HSIC's 10-K?

Notable risk changes: Opioid litigation exposure quantified for first time with 0.4% maximum sales cap - provides transparency on contingent liability but confirms ongoing legal risk in healthcare distribution; Significant reliance on variable-rate debt (SOFR-indexed) across multiple facilities creates earnings volatility in current high-interest-rate environment; no hedging strategy disclosed; Accounts Receivable…

About this analysis

Primary source:
View this 10-K on SEC EDGAR
Additional data:
Yahoo Finance (market data)
Method:
StockHuntr analyzes filings with AI — see our methodology.
Analysis as of:
February 25, 2025
Published by:
StockHuntr

For research and education only. Nothing here is investment advice.

📄

Fetching Filing from SEC

Downloading filing HTML from SEC.gov...

15% Complete
1
Fetch filing from SEC
2
Parse document sections
3
Fetch prior filing
4
Analyze risk factors
5
Analyze management sentiment
6
Extract financial metrics
7
Compare to analyst consensus
8
Run ML prediction model
9
Finalize analysis

Note: Analysis typically takes 30-60 seconds. We're fetching real SEC filing data and running AI analysis on the actual content.